FATE Q3 2017 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$143M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+0.0% YoY

Gross Profit

-$8M-736.1% margin

Operating Income

-$10M-1007.8% margin

Net Income

-$11M-1041.3% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$871,000

Balance Sheet

Total Assets

$73M

Total Liabilities

$27M

Stockholders' Equity

$46M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+0.0%
Gross Profit	-$8M	-$6M	-30.7%
Operating Income	-$10M	-$8M	-23.3%
Net Income	-$11M	-$9M	-22.3%